实现 Project Optimus 的承诺:在瘤学药物开发中优化剂量的挑战和新兴机会
Wei Gao1, Jiang Liu2, Blerta Shtylla3
1Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA.
CPT: pharmacometrics & systems pharmacology
|November 16, 2023
概括
项目Optimus旨在改革瘤药物开发剂量选择. 通过整合各种数据和使用定量建模,它旨在优化药物剂量,以获得更好的患者结果和降低毒性.
科学领域:
- 在瘤学瘤学.
- 药物开发 药物开发
- 监管科学 监管科学
背景情况:
- 项目Optimus是美国食品和药物管理局瘤卓越中心的倡议.
- 它旨在改革瘤药物开发中的剂量选择和优化范式.
- 它汇集了制药公司,监管机构,学术机构和患者倡导者.
研究的目的:
- 解决瘤学剂量优化的挑战,包括多维性,癌症/患者异质性,长期耐受性和生物标志物限制.
- 通过全证方法和基于模型的药物开发,提供对剂量优化的见解.
- 建立一个量化知识库,整合各种数据来源,以建立基于证据的药物剂量.
主要方法:
- 利用定量建模工具来整合各种数据源.
- 在剂量优化中考虑暴露,疾病生物学,疗效,毒性和患者因素.
- 采用全面证据方法和基于模型的药物开发原则.
主要成果:
- 开发一个关于瘤药物剂量的定量知识库.
- 通过考虑多个因素来优化药物剂量的洞察力.
- 在瘤学药物开发中合理优化剂量的框架.
结论:
- 在瘤学药物开发中可以实现合理的剂量优化.
- 优化剂量可以通过最大限度地提高治疗效益和最大限度地减少毒性来改善患者的治疗结果.
- 该项目提供了通往更有效,更安全的癌症治疗的途径.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drug Discovery: Overview
8.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.0K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Nonlinear Pharmacokinetics: Overview
391
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
391
Dose-Response Relationship: Overview
3.2K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.2K


